🇺🇸 FDA
Patent

US 7314631

Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)

granted A61KA61K2039/5254A61K2039/5256

Quick answer

US patent 7314631 (Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Dec 27 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Jan 01 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 27 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61K, A61K2039/5254, A61K2039/5256, A61K2039/70, A61K39/12